Ganga Pharmaceuticals (539680) H1 24/25 earnings summary

Executive summary

• Board approved unaudited financial results for the half year ended September 30, 2024, with auditor's limited review confirming no material misstatements.

Financial highlights

• Revenue from operations for H1 FY25 was ₹13,112.74 thousand, slightly down from ₹14,164.40 thousand in H2 FY24 and ₹13,193.36 thousand in H1 FY24.

• Total income for H1 FY25 stood at ₹16,041.99 thousand, up from ₹15,671.09 thousand in H2 FY24 and ₹14,081.60 thousand in H1 FY24.

• Net profit for H1 FY25 was ₹240.64 thousand, compared to ₹303.96 thousand in H2 FY24 and ₹162.23 thousand in H1 FY24.

• Basic EPS for H1 FY25 was ₹0.05, compared to ₹0.07 in H2 FY24 and ₹0.04 in H1 FY24.

• Cash and cash equivalents increased to ₹4,770.44 thousand as of September 30, 2024, from ₹298.30 thousand as of March 31, 2024.

Outlook and guidance

• Company continues to focus on its Ayurveda business, with funds from recent equity and warrant issues being utilized as planned.